X
Please Wait
Applying Filters...
1. Salol
1. 118-55-8
2. Phenyl 2-hydroxybenzoate
3. Salol
4. Phenol Salicylate
5. Salphenyl
6. Musol
7. Benzoic Acid, 2-hydroxy-, Phenyl Ester
8. 2-phenoxycarbonylphenol
9. Salicylic Acid, Phenyl Ester
10. 2-hydroxybenzoic Acid Phenyl Ester
11. Phenyl-2-hydroxybenzoate
12. 2-hydroxy-benzoic Acid Phenyl Ester
13. Fenylester Kyseliny Salicylove
14. Nsc 33406
15. Salicylic Acid Phenyl Ester
16. Nsc-33406
17. Seesorb 201
18. Seesorb K 201
19. 2-hydroxybenzoic Acid, Phenyl Ester
20. Fema No. 3960
21. Chebi:34918
22. 28a37t47qo
23. Nsc33406
24. Phenyl Salicylate Melting Point Standard
25. Ncgc00090887-02
26. Dsstox_cid_1957
27. Dsstox_rid_76426
28. Dsstox_gsid_21957
29. Cas-118-55-8
30. Ccris 4859
31. Phenyl Salicylate [nf]
32. Einecs 204-259-2
33. Mfcd00002213
34. Fenylester Kyseliny Salicylove [czech]
35. Brn 0393969
36. Phenylsalicylate
37. Unii-28a37t47qo
38. Ai3-00195
39. Phenyl-salicylate
40. Salicylic Acid Phenyl
41. Salicylic Phenyl Ester
42. Salol [vandf]
43. Salol [hpus]
44. Wln: Qr Bvor
45. Salol [mart.]
46. Oprea1_020651
47. Oprea1_771794
48. Schembl24326
49. Bidd:er0018
50. Phenyl Salicylate [mi]
51. Chembl1339216
52. Dtxsid6021957
53. Phenyl Salicylate [fhfi]
54. Phenyl Salicylate [inci]
55. Zinc38545
56. Phenyl Salicylate [vandf]
57. Phenyl Salicylate, >=99%, Fg
58. Phenyl Salicylate [usp-rs]
59. Phenyl Salicylate [who-dd]
60. Str06361
61. Tox21_113459
62. Tox21_201811
63. Tox21_302949
64. Phenyl Salicylate, Crystal, Purified
65. Stk052177
66. Akos000121203
67. Nsc33406nsc 33406
68. Tox21_113459_1
69. Db11071
70. Ps-7960
71. Ncgc00090887-01
72. Ncgc00090887-03
73. Ncgc00090887-04
74. Ncgc00090887-05
75. Ncgc00091499-03
76. Ncgc00256612-01
77. Ncgc00259360-01
78. Ac-11469
79. Phenyl Salicylate, Reagentplus(r), 99%
80. Db-024372
81. Ft-0689174
82. S0017
83. Ab00443435-03
84. A804056
85. Phenyl Salicylate, Vetec(tm) Reagent Grade, 98%
86. Q421259
87. Sr-01000883691
88. J-200110
89. Sr-01000883691-1
90. Z57206005
91. Mettler-toledo Calibration Substance Me 30034252, Phenyl Salicylate
92. Mettler-toledo Calibration Substance Me 30034252, Phenyl Salicylate, Traceable To Primary Standards
93. Phenyl Salicylate Melting Point Standard, Approximately 41 Degrees, United States Pharmacopeia (usp) Reference Standard
94. Phenyl Salicylate Melting Point Standard, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 214.22 g/mol |
|---|---|
| Molecular Formula | C13H10O3 |
| XLogP3 | 3.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 214.062994177 g/mol |
| Monoisotopic Mass | 214.062994177 g/mol |
| Topological Polar Surface Area | 46.5 Ų |
| Heavy Atom Count | 16 |
| Formal Charge | 0 |
| Complexity | 233 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Pain and fever.
Phenyl salicylate has several medical uses. It can be used as an analgesic to relieve pain, as an antiseptic with antibacterial effect as well as a kind of antipyretic for the treatment of fever. It is also used for the treatment of inflammation in the lower urinary tract. It is no longer commonly applied to human medical practice but is still used in veterinary medicine [MSDS]. When it is combined with methenamine, benzoic acid, phenyl salicylate, methylene blue, and hyoscyamine sulfate, it is used to relieve the discomfort, pain, frequent urge to urinate, and cramps/spasms of the urinary tract caused by a urinary tract infection or a diagnostic procedure.
G - Genito urinary system and sex hormones
G04 - Urologicals
G04B - Urologicals
G04BX - Other urologicals
G04BX12 - Phenyl salicylate
Absorption
Rapidly absorbed. Refer to [DB00945] for detailed salicylate absorption information.
Route of Elimination
Please refer to [DB00945] for the route of elimination.
Volume of Distribution
Steady-state plasma salicylate concentrations increase more than proportionally with increasing dosages; the time required to reach steady state increases with increasing daily dose. Dosage intervals of 8-12 h are sufficient to maintain plasma salicylate concentrations in the normal therapeutic anti-inflammatory concentration range.
Clearance
Please refer to [DB00945] for more information.
Hydrolyzed to salicylic acid. Salicylic acid elimination kinetics are dependent on drug concentration because of the limited capacity of two major biotransformation pathways: formation of salicyluric acid and of salicyl phenolic glucuronide. Metabolism of this drug occurs mainly in the liver, like other salicylates. Metabolism of salicylic acid occurs through glucuronide formation (to produce salicyluric acid), and salicyl phenolic glucuronide), conjugation with glycine (to produce salicyluric acid), and oxidation to form gentisic acid. The rate of formation of salicyl phenolic glucuronide and salicyluric acid are easily saturated at low salicylic acid concentrations and their formation can be described by Michaelis-Menten kinetics.
Mean half-life of 1.1 h.
Inhibits the activity of the enzyme known as cyclooxygenase (COX) which causes the formation of prostaglandins, substances which cause inflammation, swelling, pain, and fever. For more information, refer to the drug entry [DB00945].
Market Place
